Добро пожаловать, посетитель!
Пожалуйста, войдите или зарегистрируйтесь.    Забыли пароль?

Posted by benen1982 on 28.11.2016 21:04:33: tarceva roche
(1 чел.) (1) Гость
Добро пожаловать на форум faizov.kz
ВнизСтраница: 1
Сообщения темы: Posted by benen1982 on 28.11.2016 21:04:33: tarceva roche
#5025
Posted by benen1982 on 28.11.2016 21:04:33: tarceva roche 2 г., 3 мес. назад Репутация: 0
High Quality - Low Cost Anti-Cancer Drugs
You Can Trust -> « TARCEVA ( erlotinib ) »
*
Erlotinib is eliminated with a median half-life of 36.2 hours in patients receiving the single-agent TARCEVA 2 nd /3 rd line regimen. Time to reach steady state plasma concentration would therefore be 7-8 days.
regimens (10). Erlotinib was also superior to placebo with respect
As for the other two TKIs considered by the PBAC, the economic evaluation for erlotinib compared:
Cheapest Tarceva in Baltimore
Method for the preparation of Erlotinib of formula (I) or a salt thereof:
Cost of Tarceva (erlotinib) 150mg Tablets in China
Coverage of the Marketed data of the Tarceva on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
alliance.pp.ua/index.php?option=com_kune...=1067&Itemid=145
seeding, cells were treated with 0.5 to 6 A mol/L erlotinib or with vehicle for
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Erlotinib EMA drug label .
Or pancreatic cancer when combined with a certain other medicine, side effects Patients using Erlonat is a Kinase inhibitor which is primarily used to treat cell lung cancer. Wash tablets down buy erlonat with full glass of water. Whether listed below or not, notify your physician promptly if you notice any side effects. Coughing Fever Weakness Chest pains Severe or persistent nausea Vomiting Diarrhea Eye discomfort Irritated or dry skin Inward growing eyelashes Unusual bruising or bleeding Loss of appetite.
kras-rogaining.ru/index.php?option=com_k...d=22114&Itemid=0
Erlotinib Hydrochloride Salt
实施例3 (盐酸埃罗替尼晶型A的制备) (Preparation of Erlotinib Hydrochloride Form A) Example 3
9. 根据权利要求8所述盐酸埃罗替尼晶型A的制备方法,其特征在于,所述醚 类的氯化氬溶液为乙醚氯化氢溶液或曱基^k丁基醚氯化氢溶液。 According to claim 8, wherein the preparation of nylon Erlotinib Hydrochloride Form A, wherein said chlorinated ether is argon solution of hydrogen chloride in ether solution or 曱 yl ^ k-butyl ether solution of hydrogen chloride.
1.5小时滴完,滴加毕,再保温3小时,保温毕,过滤,用10mL乙瞇淋洗湿品, 抽干后,放入20〜30。C真空烘箱中干燥,得干品:10.1g,收率:98.3%。 In a clean dry in a 250mL four burn and tile, and put erlotinib free base monomer 10g, trichloromethyl Yue alkyl 100mL, start stirring, water of cooling to -20
Crude erlotinib hydrochloride (37 gm, obtained in reference example 1), water (370 ml) and chloroform (370 ml) are taken into a reaction flask at 25 - 30 0 C and start stirring. The contents are heated to 50 - 55 0 C, sodium hydroxide solution is added at 50 - 55 0 C and then stirred for 15 minutes at 50 0 C (clear solution not observed). To the reaction mass added chloroform (200 ml) and methanol (60 ml) and stirred for 15 minutes at 50 0 C (clear solution observed). Separated the layers at 50 0 C, the organic layer is washed with water (200 ml) at 50 0 C and then combined the organic layers. To the organic layer added methanol (60 ml) dried over sodium sulfate and distilled the total solvent under vacuum at 50 - 55 0 C. To the residue added n-heptane (300 ml) and stirred for 30 minutes at 25 - 30 0 C. Filtered the material, washed with n-heptane (70 ml) and then dried the material at 60 - 65 0 C under vacuum for 3 hours 30 minutes to give 34 gm of anhydrous erlotinib free base (HPLC Purity: 98.2%, Moisture Content: 0.2%).
Erlotinib Hydrochloride India
When should I discontinue, withhold or modify the dose of Erlotinib
www.actual-print.ru/component/kunena/3--...sm-of-resistance#882
[Show abstract] [Hide abstract] ABSTRACT: Although treatment with cytotoxic agents has produced modest survival improvement in patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau has been reached with currently available chemotherapeutic regimens. Increasing knowledge regarding the properties of malignant neoplasms has identified a number of potential therapeutic targets. The epidermal growth factor receptor (EGFR) is one of these targets. Preclinical models have revealed that tumour growth can be inhibited by monoclonal antibodies directed against EGFR and EGFR-specific tyrosine kinase inhibitors. Erlotinib (Tarceva trade mark; OSI Pharmaceuticals, Genentech and Roche), a quinazoline derivative with good oral absorption, is one of several EGFR tyrosine kinases that has been studied in clinical trials. In a Phase I study, mild diarrhoea and mild rash were the most common toxicities. At a dose of 200 mg/day, diarrhoea was the dose-limiting toxicity. The observation that EGFR overexpression is relatively common in NSCLC led to a Phase II trial of erlotinib at the maximum-tolerated dose (150 mg/day) in previously treated NSCLC patients. Erlotinib produced a 12% response rate and there was no apparent relationship between response and tumour EGFR levels. More recent reports suggest that patients who develop a rash have higher responses. Based on its single agent activity, erlotinib has been evaluated in two Phase III trials which compared erlotinib plus chemotherapy to chemotherapy alone in previously untreated NSCLC patients. Erlotinib has also been compared to placebo in a Phase III trial which was limited to advanced stage NSCLC patients whose disease had progressed after two previous chemotherapy regimens. The optimum use of erlotinib in NSCLC will be determined by the results of the completed and future Phase III trials.
Looking at the patients with an EGFR mutation, I would contend that the results are unclear. The difference in RR is pretty negligible: 67% with Tarceva, and 73% with chemo/Tarceva, and both results right in the typical range what you see in the various other trials of patients with an EGFR mutation who receive an EGFR TKI alone. Both median PFS and median OS are numerically a little higher with chemo/Tarceva (15.7 vs. 17.2; and 31.3 vs. 39.0), but these results are based on just 33 patients per arm, which makes a median a rather insensitive variable. But it’s clear that there isn’t a penalty in giving concurrent chemo/Tarceva here.
Treatment with Avastin, Tarceva, or other agents, either investigational or marketed, that act by either EGFR inhibition or anti-angiogenesis mechanisms
Erlonat 150 Mg Tablets suppliers, Wholesaler, Distributor, Delhi India.With our rich industry experience and deep knowledge, we are offering a qualitative range of Erlonat 150 Mg Tablets . These Erlotinib medicines are processed in compliance with medical standards & latest methodology using optimum quality ingredients. Our Erlotinib medicine is used for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. Provided Erlotinib medicines are available from us in bulk quantity at nominal price within a promised time frame.
TARCEVA 150 MG TABLET
In another study, Ifetkhar Khan, PhD. of University College London, and colleagues found that erlotinib has about an 80% chance of being cost effective at thresholds between ₤50,000 to ₤60,000 ($71,023 to $85,227) among elderly NSCLC patients unfit for chemotherapy. "Erlotinib is potentially cost-effective for this population, for which few treatment options apart from best supportive care are available," the researchers pointed out.
NSCLC Non-small cell lung cancer OSI-906 IGF-IR Tarceva
megaservis-pk.ru/index.php/kunena/dobro-...arceva-stops-working
Your pharmacist can provide more information about erlotinib.
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors CANCER CHEMOTHERAPY AND PHARMACOLOGY Padda, S. K. Krupitskaya, Y. Chhatwani, L. Fisher, G. A. Colevas, A. D. Pedro-Salcedo, M. S. Decker, R. Latz, J. E. Wakelee, H. A. 2012 ; 69 (4). 1013-1020
bus-rostov.ru/forum/razdel-predlozhenij/...y-tarceva-in-uk.html
Additional information about Tarceva can be found on the Genentech website, www.tarceva.com
Review: could Tarceva cause Stomach Pain?
If you want to ask your question on the FORUM, please use the button Zadaj nowe pytanie o Tarceva na forum
Hi, If a person is very elderly and not a good candidate for chemotherapy because of marginal kidney function and frailty, could Tarceva be prescribed as a trial before trying chemo? Thank you, Terri
Thanks, ssflxl. I have used both the baby oil and the almond oil, and am trying to learn to be more conscientious about moisturising more than once a day, as no one wants skin like an elephant. It all takes so much time! I’ll investigate the Restasis, but what I have at the moment is more of an itchy-skin problem than a dry-eye problem. It’s the kind of thing I got when I was little and spent too much time with our Siamese cat. I suppose it’s possible that it’s nothing to do with the Tarceva at all, but I have been through all the other obvious causes with a friendly pharmacist. And alas, we have no cat .
While Coventry hasn't approved coverage of Tarceva, it had no problem approving Casey's enrollment in a clinical trial for another cancer drug, Iressa. Iressa is not FDA approved for treating any cancers, and it was actually pulled off the market in 2004 for ineffectiveness. It is still being tested. According to Coventry, it is Casey's only option for now.
Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account (see sections 4.2 and 5.1).
stom05.ru/kunena/reklamnyj-razdel/2981-p...ell-lung-cancer.html
Similar to Geftinat (gefitinib), Erlonat (Erlotinib) specifically targets theepidermal growth factor receptor (EGFR) tyrosine kinase, which is highly expressed and occasionallymutated in various forms of cancer. It binds in a reversible fashion to the adenosine triphosphate(ATP) binding site of the receptor.[1] For the signal to be transmitted, two members of the EGFR family need to come together to form a homodimer. These then use the molecule of ATP to autophosphorylate each other, which causes a conformational changein their intracellular structure, exposing a further binding site for binding proteins that cause a signal cascade to the nucleus. By inhibiting the ATP, autophosphorylation is not possible and the signal is stopped.
Trials of EGFR-targeted agents with cytotoxic chemotherapy or other targeted therapies have also been conducted. In a separate phase I trial, when erlotinib was administered in conjunction with docetaxel and carboplatin in 48 patients, a slightly lower response rate was reported than in a historical control with docetaxel and carboplatin alone (52 vs 59 % ; Siwak et al . 2010 ). More recently, a phase II study of 56 patients demonstrated no improvement in pathological CR rates compared with historical experience with erlotinib added to carboplatin and paclitaxel in the first-line therapy for ovarian cancer ( Blank et al . 2010 ). Tumour specimens were analysed for EGFR amplification in 20 patients, but no statistically significant correlation was observed between amplification status and response. An additional study comparing the combination of erlotinib and the anti-angiogenic agent bevacizumab also did not show any improvement compared with bevacizumab alone. Similarly, vandetanib, a small molecule inhibitor of VEGFR and EGFR signalling, did not demonstrate significant clinical benefit in recurrent ovarian cancer ( Annunziata et al . 2010 ). In addition to small molecule inhibitors, monoclonal antibodies that bind directly to the extracellular domain of EGFR to block EGFR activation or reduce surface EGFR levels have also been tested in clinic. The clinical activity of these therapeutic antibodies, such as cetuximab (Erbitux, ImClone LLC, Bridgewater, NJ, USA) and matuzumab (EMD7200), in ovarian cancer appears to be very limited ( Siwak et al . 2010 ).
"Erlotinib-nonresponsive" patients are those who either progressed immediately during treatment with erlotinib (i.e. after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months.
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Clinicians, patients and the public have until 29th April1 to voice their approval for the revised preliminary NICE decision. It is expected that NICE will issue its final decision by September. NICE is not re-reviewing its guidance recommending first-line treatment with erlotinib.
cveklov.pp.ua/index.php/forum/razdel-pre...rochloride-structure
Finally, they started chemo, giving her both Gemzar and Tarceva. Ironically, my mom was a research toxicologist for Eli Lilly and tested Gemzar almost 20 years ago while working for them. The chemo seemed to be working. The cells were showing signs of necrosis in her liver and the tumor on the head of her pancreas was shrinking. Then, at the beginning of April, she was feeling a lot better but her right arm started swelling.
The article presents information about a study which has revealed that Tarceva benefits elderly lung cancer patients. Phase II study has found that OSI Pharmaceuticals Inc. Genentech Inc. and Roche AG's Tarceva is particularly beneficial in elderly patients with previously untreated lung.
26 Aug 2014 . Read about the cancer treatment drug erlotinib, otherwise known as Tarceva . including what it is, how it works and possible side effects.
Nel 50 % circa dei pazienti trattati con Tarceva si è manifestata diarrea (inclusi casi molto rari ad esito fatale); la diarrea di intensità moderata o grave deve essere trattata, ad esempio con loperamide. In alcuni casi può essere necessario ridurre la dose. Negli studi clinici le dosi sono state ridotte di 50 mg per volta. Le riduzioni di dose di 25 mg per volta non sono state studiate. In caso di diarrea grave o persistente, nausea, anoressia o vomito associato a disidratazione, si deve interrompere la somministrazione di Tarceva e approntare i provvedimenti adeguati al trattamento della disidratazione (vedere paragrafo 4.8). Sono stati riportati rari casi di ipopotassemia ed insufficienza renale (inclusi casi ad esito fatale). Alcuni casi erano secondari ad una disidratazione severa causata da diarrea, vomito e/o anoressia, mentre altri erano dovuti alla chemioterapia concomitante. Nei casi di diarrea più grave o persistente, o che porti a disidratazione, particolarmente nei gruppi di pazienti con fattori di rischio aggravanti (in particolare in concomitanza con un trattamento chemioterapico e altri farmaci, sintomi o patologie o altre condizioni predisponenti, inclusa l’età avanzata) si deve interrompere la somministrazione di Tarceva e approntare provvedimenti adeguati atti alla reidratazione intensiva del paziente per via endovenosa. Inoltre, la funzione renale e gli elettroliti sierici, incluso il potassio, devono essere monitorati nei pazienti a rischio di disidratazione.
Cumpar tarceva, astept un raspuns la adresa de email ioanaioana1994@yahoo.ro
FAST-ACT is a Phase II randomized, double-blind trial of sequential Tarceva and chemotherapy as first-line treatment in Asian patients with stage IIIB/IV NSCLC. The study involved 154 patients from Australia, China (including Hong Kong), Indonesia, Korea, Philippines, Taiwan and Thailand.
faizo
Platinum Boarder
Постов: 5161
graph
Пользователь вне форума Кликните здесь, чтобы посмотреть профиль этого пользователя
Для добавления сообщений Вы должны зарегистрироваться или авторизоваться
 
ВверхСтраница: 1

Вопрос-ответ


Задать свой вопрос

Сейчас на сайте

Сейчас 1426 гостей онлайн
You are here: